U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Osimertinib (Tagrisso): CADTH Reimbursement Review: Therapeutic area: Non–small cell lung cancer [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Mar.

Cover of Osimertinib (Tagrisso)

Osimertinib (Tagrisso): CADTH Reimbursement Review: Therapeutic area: Non–small cell lung cancer [Internet].

Show details
The x-axis ranges from 0 months to 54 months. The Kaplan-Meier curves begin to separate at approximately 8 months with the osimertinib curve on top, then the curves cross at approximately 40 months. The osimertinib curve plateaus at 40 months; the placebo curve plateaus at 30 months.

Figure 4Kaplan-Meier Plot of OS in the ADAURA Trial — FAS, Stage II to Stage IIIA Population

Source: Clinical Study Report.13

AZD9291 = osimertinib; FAS = full analysis set; OS = overall survival.

From: Clinical Review

Copyright © 2022 Canadian Agency for Drugs and Technologies in Health.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Contents

Views

  • Cite this Page
  • PDF version of this title (6.1M)

Other titles in this collection

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...